MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLENMARK PHARMA (pharmaceuticals)
- GLENMARK PHARMA Financial Data
GLENMARK PHARMA Fact Sheet 
(GLPH)
Update: Richa is Very Bullish on this Little-known Smallcap Stock
Here is the latest financial fact sheet of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA quarterly results and GLENMARK PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
GLENMARK PHARMA Price History
| 1 Day | % | 0.3 |
| No. of shares | m | 282.17 |
| 1 Week | % | 10.1 |
| 1 Month | % | -2.7 |
| 1 Year | % | -41.9 |
| 52 week H/L | Rs | 690.6/348.9 |
GLENMARK PHARMA Financials
| No. of Mths Year Ending |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
5-Yr Chart Click to enlarge
|
|---|
| GLENMARK PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 993 | 930 | 712 | 660 | 573 | |
| Low | Rs | 729 | 517 | 484 | 168 | 195 | |
| Sales per share (Unadj.) | Rs | 318.0 | 320.6 | 349.6 | 377.1 | 387.8 | |
| Earnings per share (Unadj.) | Rs | 39.3 | 28.5 | 32.8 | 27.5 | 34.4 | |
| Diluted earnings per share | Rs | 39.3 | 28.5 | 32.8 | 27.5 | 34.4 | |
| Cash flow per share (Unadj.) | Rs | 48.7 | 39.2 | 44.3 | 42.3 | 50.1 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | |
| Adj. dividends per share | Rs | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | |
| Avg Dividend yield | % | 0.2 | 0.3 | 0.3 | 0.6 | 0.7 | |
| Book value per share (Unadj.) | Rs | 159.2 | 182.6 | 198.3 | 214.7 | 249.6 | |
| Adj. book value per share | Rs | 159.2 | 182.6 | 198.3 | 214.7 | 249.6 | |
| Shares outstanding (eoy) | m | 282.17 | 282.17 | 282.17 | 282.17 | 282.17 | |
| Price / Sales ratio | x | 2.7 | 2.3 | 1.7 | 1.1 | 1.0 | |
| Avg P/E ratio | x | 21.9 | 25.4 | 18.2 | 15.0 | 11.2 | |
| P/CF ratio (eoy) | x | 17.7 | 18.5 | 13.5 | 9.8 | 7.7 | |
| Price / Book Value ratio | x | 5.4 | 4.0 | 3.0 | 1.9 | 1.5 | |
| Dividend payout | % | 5.1 | 7.0 | 6.1 | 9.1 | 7.3 | |
| Avg Mkt Cap | Rs m | 242,989 | 204,205 | 168,617 | 116,775 | 108,353 | |
| Total wages/salary | Rs m | 16,408 | 18,718 | 20,561 | 22,548 | 23,437 | |
| GLENMARK PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 89,731 | 90,458 | 98,655 | 106,410 | 109,439 | |
| Other income | Rs m | 374 | 914 | 2,081 | 1,596 | 502 | |
| Total revenues | Rs m | 90,105 | 91,372 | 100,736 | 108,006 | 109,941 | |
| Gross profit | Rs m | 19,558 | 16,154 | 17,530 | 17,310 | 21,289 | |
| Depreciation | Rs m | 2,644 | 3,019 | 3,259 | 4,172 | 4,436 | |
| Interest | Rs m | 2,373 | 2,856 | 3,346 | 3,773 | 3,531 | |
| Profit before tax | Rs m | 14,914 | 11,193 | 13,006 | 10,961 | 13,825 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 3,827 | 3,155 | 3,756 | 3,201 | 4,124 | |
| Profit after tax | Rs m | 11,088 | 8,039 | 9,250 | 7,760 | 9,701 | |
| Gross profit margin | % | 21.8 | 17.9 | 17.8 | 16.3 | 19.5 | |
| Effective tax rate | % | 25.7 | 28.2 | 28.9 | 29.2 | 29.8 | |
| Net profit margin | % | 12.4 | 8.9 | 9.4 | 7.3 | 8.9 | |
| GLENMARK PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 68,746 | 69,887 | 66,968 | 68,036 | 73,596 | |
| Current liabilities | Rs m | 27,027 | 32,879 | 40,211 | 41,260 | 42,010 | |
| Net working cap to sales | % | 46.5 | 40.9 | 27.1 | 25.2 | 28.9 | |
| Current ratio | x | 2.5 | 2.1 | 1.7 | 1.6 | 1.8 | |
| Inventory Days | Days | 5 | 5 | 5 | 6 | 7 | |
| Debtors Days | Days | 98 | 94 | 81 | 83 | 86 | |
| Net fixed assets | Rs m | 35,780 | 42,864 | 52,090 | 64,255 | 67,093 | |
| Share capital | Rs m | 282 | 282 | 282 | 282 | 282 | |
| "Free" reserves | Rs m | 44,629 | 51,248 | 55,664 | 60,286 | 70,148 | |
| Net worth | Rs m | 44,911 | 51,530 | 55,946 | 60,568 | 70,430 | |
| Long term debt | Rs m | 45,363 | 41,418 | 35,738 | 40,430 | 38,888 | |
| Total assets | Rs m | 104,526 | 112,751 | 119,058 | 132,291 | 140,689 | |
| Interest coverage | x | 7.3 | 4.9 | 4.9 | 3.9 | 4.9 | |
| Debt to equity ratio | x | 1.0 | 0.8 | 0.6 | 0.7 | 0.6 | |
| Sales to assets ratio | x | 0.9 | 0.8 | 0.8 | 0.8 | 0.8 | |
| Return on assets | % | 12.9 | 9.7 | 10.6 | 8.7 | 9.4 | |
| Return on equity | % | 24.7 | 15.6 | 16.5 | 12.8 | 13.8 | |
| Return on capital | % | 19.1 | 15.1 | 17.8 | 14.6 | 15.9 | |
| Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
| Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 56,152 | 36,317 | 62,998 | 47,737 | 35,753 | |
| Fx outflow | Rs m | 8,084 | 9,720 | 22,859 | 18,881 | 12,023 | |
| Net fx | Rs m | 48,067 | 26,598 | 40,140 | 28,856 | 23,729 | |
| GLENMARK PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 6,574 | 16,481 | 13,242 | 13,924 | 11,312 | |
| From Investments | Rs m | -7,123 | -10,133 | -6,990 | -7,835 | -6,752 | |
| From Financial Activity | Rs m | 5,432 | -4,685 | -7,387 | -4,447 | -4,418 | |
| Net Cashflow | Rs m | 1,992 | 1,770 | -2,971 | 1,740 | 278 | |
Share Holding
Shareholding as on Mar 2022
|
Company Information
|
|||||||||||||||||||||||||||||||||||||
| CHM: Glenn Saldanha | COMP SEC: Harish Kuber | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.6 |
More Pharmaceuticals Company Fact Sheets: SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN
Compare GLENMARK PHARMA With: SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN
Today's Market
Sensex, Nifty Rebound from Day's Low to End Flat; IT & Auto Stocks Witness Buying(Closing)
Indian share markets witnessed a volatile trading session today as crude oil prices rebounded following last week's rout.
Views on news
5 Takeaways from Sun Pharma's Q4 Results (Views On News)
May 30, 2022It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Why Divi's Lab Share Price is Falling (Views On News)
May 24, 2022Here's why Divi's Lab's stock fell over 10% in two days.
Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)
May 23, 2022For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)
May 19, 2022During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)
Apr 13, 2022The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
More Views on NewsMost Popular
4 Sectors to Watch for Future Multibagger Stocks (Views On News)
Jun 17, 2022With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Best Monopoly Stocks to Own in 2022 
(Views On News)
Jun 18, 2022
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
Is it Time to Start Buying Stocks Selectively? (Profit Hunter)
Jun 16, 2022Some sectors have corrected by 50%. Do they merit a look?
The One Smallcap Stock I'll Recommend Now (Profit Hunter)
Jun 21, 2022This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
When Will the Stock Market Recover? (Views On News)
Jun 15, 2022This is how you can tell the market is going to recover.
MoreOUR TOP 5 IDEAS
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA - VINEET LABORATORIES COMPARISON
COMPARE GLENMARK PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks in 2022
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.